Currently, PI3K/AKT/mTOR signaling has been reported as an emerging source of lung cancer aggressiveness. The development of therapies targeting PI3K/AKT/mTOR signaling is receiving extensive attention from researchers, and new drugs continue to be discovered [130]. This evidence concerns the gene MTOR and lung cancer.